Oncology /Immuno-oncology Platform
Non-Human Primates Platform
Inflammation/Autoimmune Diseases Model
Metabolic/Liver/Cardiovascular Diseases Model
Non-alcoholic steatohepatitis (NASH) is a liver disease with signs of steatosis, liver inflammation and fibrosis manifested histologically. Metabolic syndrome, obesity and hepatic insulin resistance, in particular, are considered as driving factors in the etiology of NASH.There is currently no dedicated treatment approved for NASH, yet there is a growing incidence of this disease in developed countries. This has prompted substantial efforts to identify novel drug therapies to correct underlying metabolic problems and to prevent or alleviate hepatic fibrosis in NASH. Available models of NASH at PharmaLegacy show different utility in drug discovery including MCD-induced NASH in rats and STZ-HFD-induced in mice.
· Male Wistar rats
· Animals were fed an MCD diet for a period of 8 weeks to establish the NASH model
· Animals were treated with vehicle or reference throughout the entire 8-week study